Tempus AI (NASDAQ:TEM) Coverage Initiated at Roth Capital

Equities research analysts at Roth Capital started coverage on shares of Tempus AI (NASDAQ:TEM) in a report released on Tuesday, Benzinga reports. The brokerage set a “neutral” rating and a $67.00 price target on the stock. Roth Capital’s price target indicates a potential upside of 3.68% from the company’s current price.

Several other equities analysts have also recently issued reports on the stock. Cantor Fitzgerald started coverage on shares of Tempus AI in a research note on Wednesday, September 2nd. They issued an “overweight” rating and a $80.00 price objective on the stock. Wolfe Research assumed coverage on shares of Tempus AI in a research note on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Lake Street Capital lowered shares of Tempus AI to a “hold” rating in a research note on Monday, July 20th. Finally, Stifel Nicolaus reduced their price objective on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research report on Monday, August 3rd. Eleven investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Tempus AI has an average rating of “Hold” and a consensus target price of $68.71.

Tempus AI Price Performance

Tempus AI stock opened at $64.62 on Tuesday. The stock has a 50 day moving average of $55.90 and a two-hundred day moving average of $52.21. Tempus AI has a twelve month low of $40.77 and a twelve month high of $104.32. The stock has a market capitalization of $11.66 billion, a price-to-earnings ratio of -44.87 and a beta of 3.72. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last released its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. During the same quarter in the previous year, the company posted ($0.22) earnings per share. The company’s revenue for the quarter was up 21.6% compared to the same quarter last year. As a group, research analysts expect that Tempus AI will post -1.38 earnings per share for the current year.

Insider Buying and Selling at Tempus AI

In other news, CEO Ryan Fukushima sold 41,095 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $2,038,722.95. Following the completion of the transaction, the chief executive officer directly owned 562,463 shares of the company’s stock, valued at $27,903,789.43. This trade represents a 6.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James Rogers sold 26,313 shares of Tempus AI stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total value of $1,578,780.00. Following the transaction, the chief financial officer owned 106,024 shares of the company’s stock, valued at $6,361,440. This represents a 19.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 1,043,988 shares of company stock valued at $56,963,417. Company insiders own 24.26% of the company’s stock.

Institutional Trading of Tempus AI

A number of large investors have recently made changes to their positions in the stock. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Tempus AI in the 2nd quarter valued at about $881,000. California State Teachers Retirement System boosted its stake in shares of Tempus AI by 6,379.2% during the 2nd quarter. California State Teachers Retirement System now owns 6,977,205 shares of the company’s stock worth $404,189,000 after purchasing an additional 6,869,519 shares during the last quarter. Washington Trust Advisors Inc. boosted its stake in shares of Tempus AI by 49.1% during the 2nd quarter. Washington Trust Advisors Inc. now owns 89,166 shares of the company’s stock worth $5,165,000 after purchasing an additional 29,347 shares during the last quarter. Ameritas Advisory Services LLC purchased a new stake in shares of Tempus AI during the second quarter worth about $678,000. Finally, Straight Path Wealth Management acquired a new position in shares of Tempus AI in the second quarter valued at approximately $229,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.